307 Hospital of Military Medical Science Academy of the PLA

Beijing, China

307 Hospital of Military Medical Science Academy of the PLA

Beijing, China

Time filter

Source Type

Xiao X.,307 Hospital of Military Medical Science Academy of the PLA | Lu Y.,307 Hospital of Military Medical Science Academy of the PLA | Su H.,307 Hospital of Military Medical Science Academy of the PLA | Zhong K.,307 Hospital of Military Medical Science Academy of the PLA | And 8 more authors.
Chinese Journal of Clinical Oncology | Year: 2011

Objective: To retrospectively analyze patients with angioimmunoblastic T cell lymphoma (AITL) from a single institution, and to define the clinical features and effect of chemotherapy. Methods: Up to 23 patients with AITL in our department from Sept. 1999 to Sept. 2010 were enrolled, but only 21 patients received treatment. Up to 17 patients received CHOP-like regimens as initial chemotherapy treatments, 4 patients received L-asparaginase (L-asp) + bleomycin + dexamethasone + vindesine regimen; 1 patient was treated with radiotherapy in every group and 1 patient with high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) in every group as upfront consolidation therapy. Salvage regimen was ICE, DHAP or ProMACE/CytaBOM. Five patients received interferon or combined thalidomide for maintenance therapy; 3 patients received chidamide. Results: The median age of the 23 patients was 60 years; the male to female ratio was 1.9:1. Among all patients, 96% were in Ann Arbor stage III or IV, 57% presented with B symptoms, 22% had splenic involvement or splenomegaly. In terms of laboratory features, 39% had elevated lactate dehydrogenase (LDH), 75% had elevated beta-2 microglobulin (ß2-MG), and D-dimer levels exceeding 255 ng/mL were observed in 80% patients at diagnosis. Immunohistochemistry indicated that the positive rate for CXCL13 was 100% (12/12) and EBER was 80% (8/10). Analysis of the therapeutic effect revealed 7 patients achieved complete remission (CR) and 8 patients achieved partial remission (PR) after initial treatment with CHOP-like regimens; 1 patient achieved CR and 1 patient achieved PR after initial treatment with L-asp-based regimens. The median overall survival (OS) was 27 ( .9-51.1) months, whereas the 3- and 5-year OS was 44% and 29%. Up to 90% of the patients suffered from bone marrow depression III or IV, 33% patients suffered from pneumonia, and 1 patient suffered herpes zoster after chemotherapy. Conclusion: AITL is a distinct subtype of peripheral T-cell lymphoma with unique clinical and pathologic features. In our study, most of the patients had abnormal clotting mechanisms. AITL patients often exhibit immunodeficiency; thus, bone marrow depression and opportunistic infections during therapy cannot be neglected.

Loading 307 Hospital of Military Medical Science Academy of the PLA collaborators
Loading 307 Hospital of Military Medical Science Academy of the PLA collaborators